Skip to content

Released Nov 5, 2026, after the close

10-Q filed Nov 5, 2026, 36 days after period end · 0001193125-26-450194

Q3 2026 · 10-Q
Revenue—
Net Income-$3.32MN/M vs Q3 2025N/M vs Q2 2026
EPS Diluted-$5.92N/M vs Q3 2025N/M vs Q2 2026
Operating Income-$3,383,576N/M
Operating Cash Flowderived-$2,361,162N/M
Free Cash Flowderived-$2,361,162—

What the release said

On November 5, 2026, Revelation Biosciences, Inc. issued a press release announcing its financial results for the three and nine months ended September 30, 2026.

Revelation Biosciences issued a press release on November 5, 2026 announcing its financial results for the three and nine months ended September 30, 2026.1

Net loss for the three months ended September 30, 2026 was $3.3 million, or $5.92 per share, compared to $1.9 million, or $49.51 per share, a year earlier.2

Net loss for the nine months ended September 30, 2026 was $9.6 million, or $29.37 per share, compared to $6.4 million, or $273.33 per share, for the same period in 2025.2

Cash and cash equivalents were $9.1 million as of September 30, 2026, compared to $10.7 million as of December 31, 2025, and are stated to fund operations into the second quarter of 2027.3

Revelation released an independent market assessment showing a potential $94 billion total addressable market for Gemini and selected a full-service CRO for the upcoming acute kidney injury study.45

Net loss, three months ended September 30, 2026
$3.3 million Compared with $1.9 million for the three months ended September 30, 20252
Net loss per share, basic and diluted, three months ended September 30, 2026
$5.92 Compared with $49.51 for the three months ended September 30, 20252
Net loss, nine months ended September 30, 2026
$9.6 million Compared with $6.4 million for the nine months ended September 30, 20252
Net loss per share, basic and diluted, nine months ended September 30, 2026
$29.37 Compared with $273.33 for the nine months ended September 30, 20252
Cash and cash equivalents
$9.1 million As of September 30, 2026, compared with $10.7 million as of December 31, 20253
Potential total addressable market for Gemini
$94 billion Stated in an independent market assessment released by the company4
Thaler Agent · checked against the filing
Open the reading ›
The release

Same quarter

MetricQ3 2026Q3 2025Q3 2024Q3 2023
Net Income-$3.32M-$1.91M-$2.24M-$2.63M
EPS Diluted-$5.92-$49.51-$40.15-$9.94

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Revelation Biosciences, Inc. · CIK 1810560 · Engraved from SEC EDGAR